Issue Date: December 5, 2016
J&J negotiates to buy Actelion
Johnson & Johnson and Switzerland’s Actelion Pharmaceuticals confirm that they have held preliminary discussions about a potential transaction. According to news reports, J&J has made two bids well above Actelion’s current market value of about $21 billion. The nearly 20-year-old Swiss firm is recognized for its development of endothelin receptor antagonists, which include the pulmonary arterial hypertension drug Tracleer and newer potential PAH blockbusters Opsumit and Uptravi. For the first nine months of 2016, Actelion . . .
To view the rest of this content, please log in with your ACS ID.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society